{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T07:13:01Z","timestamp":1782889981562,"version":"3.54.5"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T00:00:00Z","timestamp":1744243200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T00:00:00Z","timestamp":1744243200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82171980"],"award-info":[{"award-number":["82171980"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"the Capital\u2019s Funds for Health Improvement and Research","award":["2022-2Z-2154"],"award-info":[{"award-number":["2022-2Z-2154"]}]},{"name":"the Pilot Project (4 th Round) to Reform Public Development of Beijing Municipal Medical Research Institute","award":["2021-1"],"award-info":[{"award-number":["2021-1"]}]},{"name":"and Science Foundation of Peking University Cancer Hospital","award":["KC2305"],"award-info":[{"award-number":["KC2305"]}]},{"name":"Isotope and Pharmaceutical Innovation Fund of National Engineering Research Center of Isotope & Pharmaceutical","award":["B00167"],"award-info":[{"award-number":["B00167"]}]},{"name":"Nuclear energy development research project","award":["2023"],"award-info":[{"award-number":["2023"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1007\/s00259-025-07251-w","type":"journal-article","created":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T06:27:48Z","timestamp":1744266468000},"page":"4044-4053","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Al18F-NOTA-HER2-BCH versus 18F-FDG PET\/CT in evaluating newly diagnosed HER2-low breast cancer patients"],"prefix":"10.1007","volume":"52","author":[{"given":"Xiaoyi","family":"Guo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayue","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangjie","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenguang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guohong","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2084-5193","authenticated-orcid":false,"given":"Zhi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,10]]},"reference":[{"issue":"1","key":"7251_CR1","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2203690","volume":"387","author":"S Modi","year":"2022","unstructured":"Modi S, Jacot W, Yamashita T, et al. Trastuzumab Deruxtecan in previously treated HER2-Low advanced breast cancer. N Engl J Med. 2022;387(1):9\u201320.","journal-title":"N Engl J Med"},{"issue":"16","key":"7251_CR2","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1056\/NEJMp058197","volume":"353","author":"HJ Burstein","year":"2005","unstructured":"Burstein HJ. The distinctive nature of HER2-positive breast cancers. N Engl J Med. 2005;353(16):1652\u20134.","journal-title":"N Engl J Med"},{"issue":"10087","key":"7251_CR3","doi-asserted-by":"publisher","first-page":"2415","DOI":"10.1016\/S0140-6736(16)32417-5","volume":"389","author":"S Loibl","year":"2017","unstructured":"Loibl S, Gianni L. HER2-positive breast cancer. Lancet. 2017;389(10087):2415\u201329.","journal-title":"Lancet"},{"issue":"5","key":"7251_CR4","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1200\/JCO.19.01455","volume":"38","author":"L Fehrenbacher","year":"2020","unstructured":"Fehrenbacher L, Cecchini RS, Geyer CE, et al. NSABP B-47\/NRG oncology phase III randomized trial comparing adjuvant chemotherapy with or without trastuzumab in High-Risk invasive breast cancer negative for HER2 by FISH and with IHC 1\u2009+\u2009or 2. J Clin Oncol. 2020;38(5):444\u201353.","journal-title":"J Clin Oncol"},{"issue":"17","key":"7251_CR5","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1200\/JCO.19.02488","volume":"38","author":"P Tarantino","year":"2020","unstructured":"Tarantino P, Hamilton E, Tolaney SM, et al. HER2-Low breast cancer: pathological and clinical landscape. J Clin Oncol. 2020;38(17):1951\u201362.","journal-title":"J Clin Oncol"},{"issue":"1","key":"7251_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41523-020-00208-2","volume":"7","author":"F Schettini","year":"2021","unstructured":"Schettini F, Chic N, Bras\u00f3-Maristany F, et al. Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer. NPJ Breast Cancer. 2021;7(1):1.","journal-title":"NPJ Breast Cancer"},{"key":"7251_CR7","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.ejca.2021.12.022","volume":"163","author":"P Tarantino","year":"2022","unstructured":"Tarantino P, Gandini S, Nicol\u00f2 E, et al. Evolution of low HER2 expression between early and advanced-stage breast cancer. Eur J Cancer. 2022;163:35\u201343.","journal-title":"Eur J Cancer"},{"issue":"17","key":"7251_CR8","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1200\/JCO.19.02318","volume":"38","author":"S Modi","year":"2020","unstructured":"Modi S, Park H, Murthy RK, et al. Antitumor activity and safety of trastuzumab Deruxtecan in patients with HER2-Low-Expressing advanced breast cancer: results from a phase Ib study. J Clin Oncol. 2020;38(17):1887\u201396.","journal-title":"J Clin Oncol"},{"issue":"4","key":"7251_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1001\/jamaoncol.2021.7239","volume":"8","author":"AI Fernandez","year":"2022","unstructured":"Fernandez AI, Liu M, Bellizzi A, et al. Examination of low ERBB2 protein expression in breast cancer tissue. JAMA Oncol. 2022;8(4):1\u20134.","journal-title":"JAMA Oncol"},{"key":"7251_CR10","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.ejca.2023.04.026","volume":"188","author":"T Geukens","year":"2023","unstructured":"Geukens T, De Schepper M, Richard F, et al. Intra-patient and inter-metastasis heterogeneity of HER2-low status in metastatic breast cancer. Eur J Cancer. 2023;188:152\u201360.","journal-title":"Eur J Cancer"},{"issue":"10","key":"7251_CR11","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.2967\/jnumed.124.267636","volume":"65","author":"B Eisses","year":"2024","unstructured":"Eisses B, van Geel JJL, Brouwers AH, et al. Whole-Body HER2 heterogeneity identified on HER2 PET in HER2-Negative, -Low, and -Positive metastatic breast cancer. J Nucl Med. 2024;65(10):1540\u20137.","journal-title":"J Nucl Med"},{"issue":"5","key":"7251_CR12","doi-asserted-by":"publisher","first-page":"724","DOI":"10.2967\/jnumed.122.264470","volume":"64","author":"MA Lumish","year":"2023","unstructured":"Lumish MA, Maron SB, Paroder V, et al. Noninvasive assessment of human epidermal growth factor receptor 2 (HER2) in esophagogastric cancer using (89)Zr-Trastuzumab PET: A pilot study. J Nucl Med. 2023;64(5):724\u201330.","journal-title":"J Nucl Med"},{"issue":"11","key":"7251_CR13","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.2967\/jnumed.123.265621","volume":"64","author":"P Mohr","year":"2023","unstructured":"Mohr P, van Sluis J, Provid\u00eancia L, et al. Long versus short axial field of view Immuno-PET\/CT: semiquantitative evaluation for (89)Zr-Trastuzumab. J Nucl Med. 2023;64(11):1815\u201320.","journal-title":"J Nucl Med"},{"issue":"1","key":"7251_CR14","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1158\/1078-0432.CCR-24-1007","volume":"31","author":"M Rediti","year":"2025","unstructured":"Rediti M, Fimereli D, Mileva M, et al. Integrating molecular imaging and transcriptomic profiling in advanced HER2-Positive breast cancer receiving trastuzumab Emtansine: an analysis of the ZEPHIR clinical trial. Clin Cancer Res. 2025;31(1):110\u201321.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"7251_CR15","first-page":"38","volume":"38","author":"SK Suman","year":"2023","unstructured":"Suman SK, Mukherjee A, Pandey U, et al. (68)Ga-Labeled trastuzumab fragments for ImmunoPET imaging of human epidermal growth factor receptor 2 expression in solid cancers. Cancer Biother Radiopharm. 2023;38(1):38\u201350.","journal-title":"Cancer Biother Radiopharm"},{"issue":"2","key":"7251_CR16","doi-asserted-by":"publisher","first-page":"262","DOI":"10.7150\/thno.13502","volume":"6","author":"J S\u00f6rensen","year":"2016","unstructured":"S\u00f6rensen J, Velikyan I, Sandberg D, et al. Measuring HER2-Receptor expression in metastatic breast cancer using [68Ga]ABY-025 affibody PET\/CT. Theranostics. 2016;6(2):262\u201371.","journal-title":"Theranostics"},{"issue":"6","key":"7251_CR17","doi-asserted-by":"publisher","first-page":"867","DOI":"10.2967\/jnumed.115.169342","volume":"57","author":"M Sandstr\u00f6m","year":"2016","unstructured":"Sandstr\u00f6m M, Lindskog K, Velikyan I, et al. Biodistribution and radiation dosimetry of the Anti-HER2 affibody molecule 68Ga-ABY-025 in breast cancer patients. J Nucl Med. 2016;57(6):867\u201371.","journal-title":"J Nucl Med"},{"issue":"9","key":"7251_CR18","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.2967\/jnumed.122.265364","volume":"64","author":"A Alhuseinalkhudhur","year":"2023","unstructured":"Alhuseinalkhudhur A, Lindman H, Liss P, et al. Human epidermal growth factor receptor 2-Targeting [(68)Ga]Ga-ABY-025 PET\/CT predicts early metabolic response in metastatic breast cancer. J Nucl Med. 2023;64(9):1364\u201370.","journal-title":"J Nucl Med"},{"issue":"3","key":"7251_CR19","doi-asserted-by":"publisher","first-page":"e232209","DOI":"10.1148\/radiol.232209","volume":"311","author":"X Guo","year":"2024","unstructured":"Guo X, Zhou N, Liu J, et al. Comparison of an Affibody-based molecular probe and (18)F-FDG for detecting HER2-Positive breast cancer at PET\/CT. Radiology. 2024;311(3):e232209.","journal-title":"Radiology"},{"issue":"9","key":"7251_CR20","doi-asserted-by":"publisher","first-page":"2775","DOI":"10.1007\/s00259-023-06232-1","volume":"50","author":"J Liu","year":"2023","unstructured":"Liu J, Guo X, Wen L, et al. Comparison of renal clearance of [(18)F]AlF-RESCA-HER2-BCH and [(18)F]AlF-NOTA-HER2-BCH in mice and breast cancer patients. Eur J Nucl Med Mol Imaging. 2023;50(9):2775\u201386.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7251_CR21","doi-asserted-by":"crossref","unstructured":"Guo X, Liu J, Lin S et al. Detectability of Al18F-NOTA-HER2-BCH PET for nodal metastases in patients with HER2-Positive breast cancer. Clin Nucl Med. 2025.","DOI":"10.1097\/RLU.0000000000005686"},{"issue":"4","key":"7251_CR22","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1200\/JCO.22.00575","volume":"41","author":"K Yamaguchi","year":"2023","unstructured":"Yamaguchi K, Bang YJ, Iwasa S, et al. Trastuzumab Deruxtecan in Anti-Human epidermal growth factor receptor 2 Treatment-Naive patients with human epidermal growth factor receptor 2-Low gastric or gastroesophageal junction adenocarcinoma: exploratory cohort results in a phase II trial. J Clin Oncol. 2023;41(4):816\u201325.","journal-title":"J Clin Oncol"},{"issue":"15","key":"7251_CR23","doi-asserted-by":"publisher","first-page":"2789","DOI":"10.1200\/JCO.22.02558","volume":"41","author":"T Nishikawa","year":"2023","unstructured":"Nishikawa T, Hasegawa K, Matsumoto K, et al. Trastuzumab Deruxtecan for human epidermal growth factor receptor 2-Expressing advanced or recurrent uterine carcinosarcoma (NCCH1615): the STATICE trial. J Clin Oncol. 2023;41(15):2789\u201399.","journal-title":"J Clin Oncol"},{"issue":"9","key":"7251_CR24","doi-asserted-by":"publisher","first-page":"2026","DOI":"10.1158\/2159-8290.CD-22-0703","volume":"12","author":"P Tarantino","year":"2022","unstructured":"Tarantino P, Curigliano G, Tolaney SM. Navigating the HER2-Low paradigm in breast oncology: new standards, future horizons. Cancer Discov. 2022;12(9):2026\u201330.","journal-title":"Cancer Discov"},{"issue":"14","key":"7251_CR25","doi-asserted-by":"publisher","first-page":"4858","DOI":"10.7150\/thno.86770","volume":"13","author":"O Bragina","year":"2023","unstructured":"Bragina O, Chernov V, Larkina M, et al. Phase I clinical evaluation of (99m)Tc-labeled affibody molecule for imaging HER2 expression in breast cancer. Theranostics. 2023;13(14):4858\u201371.","journal-title":"Theranostics"},{"issue":"2","key":"7251_CR26","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1148\/radiol.2020192828","volume":"296","author":"GA Ulaner","year":"2020","unstructured":"Ulaner GA, Carrasquillo JA, Riedl CC, et al. Identification of HER2-Positive metastases in patients with HER2-Negative primary breast cancer by using HER2-targeted (89)Zr-Pertuzumab PET\/CT. Radiology. 2020;296(2):370\u20138.","journal-title":"Radiology"},{"issue":"11","key":"7251_CR27","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1016\/j.annonc.2023.08.005","volume":"34","author":"B Uzunparmak","year":"2023","unstructured":"Uzunparmak B, Haymaker C, Raso G, et al. HER2-low expression in patients with advanced or metastatic solid tumors. Ann Oncol. 2023;34(11):1035\u201346.","journal-title":"Ann Oncol"},{"issue":"21","key":"7251_CR28","doi-asserted-by":"publisher","first-page":"2601","DOI":"10.1200\/JCO.2011.37.2482","volume":"30","author":"LS Lindstr\u00f6m","year":"2012","unstructured":"Lindstr\u00f6m LS, Karlsson E, Wilking UM, et al. Clinically used breast cancer markers such as Estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression. J Clin Oncol. 2012;30(21):2601\u20138.","journal-title":"J Clin Oncol"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07251-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-025-07251-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07251-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T10:49:30Z","timestamp":1757155770000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-025-07251-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,10]]},"references-count":28,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["7251"],"URL":"https:\/\/doi.org\/10.1007\/s00259-025-07251-w","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,10]]},"assertion":[{"value":"28 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures in this study were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964 and its later versions. Informed consent was, or its equivalent, was obtained from all patients included in the study. The clinical study was approved by the Ethics Committee of the Beijing Cancer Hospital (ethical approval no. 2019KT114). Nuclear energy development research project (2023).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from the 58 individual participants included in this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The authors declare no potential conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}}]}}